Research Questions:~To understand the clinical outcomes of patients treated with sunitinib in first line and axitinib in second line in a real world setting as therapies for metastatic and/or advanced renal cell carcinoma (mRCC).~Primary Objective:~What is the progression free survival (PFS) of patients treated in first line with sunitinib, and stratified by Memorial Sloan-Kettering Cancer Center / International Metastatic Renal Cell Carcinoma Database Consortium (MSKCC/IMDC) risk category (favourable, intermediate, poor)?~What is the progression free survival (PFS) of patients treated in second line with axitinib, and stratified by MSKCC/IMDC risk category (favourable, intermediate, poor)?~Secondary Objectives:~First Line:~What is the overall survival (OS) of all patients in first line with sunitinib, and stratified by MSKCC risk (favourable, intermediate, poor)?~What is the duration of therapy with sunitinib in first line (using time to treatment discontinuation [TTD]) for all patients and stratified by MSKCC risk (favourable, intermediate, poor)~Objective response rate (ORR)~Duration of objective response (complete response [CR] or partial response [PR])~Examine factors that predict TTD, e.g. risk stratification, or individual/grouped parameters that comprise the prognostic classification systems~Less than one year from time of diagnosis~Karnovsky performance status less than 80%~Haemoglobin less than the lower limit of normal (e.g. less than 12 g/dl)~Serum calcium great than the upper limit of normal (e.g. 10 mg/dl or : 2.5 mmol/l)~Neutrophil greater than the upper limit of normal (e.g. greater than 7.0 x109 dl)~Platelets greater than the upper limit of normal (e.g. greater than 400 000)~Lactate dehydrogenase greater than 1.5 times the upper limit of normal~Fuhrmann grade of tumour~Tumour subtype e.g. clear cell versus. non-clear cell~Safety and tolerability data reporting for first line sunitinib~Second line:~What is the OS of all patients in second line with axitinib, and stratified by MSKCC risk (favourable, intermediate, poor)?~What is the duration of therapy with axitinib in second line (using TTD) for all patients and stratified by MSKCC risk (favourable, intermediate, poor)~ORR~Duration of objective response (CR or PR)~Examine factors that predict duration of TTD, e.g. risk stratification, or individual/grouped parameters that comprise the prognostic classification systems~Less than one year from time of diagnosis~Karnovsky performance status less than 80%~Haemoglobin less than the lower limit of normal (e.g. less than 12 g/dl)~Serum calcium great than the upper limit of normal (e.g. 10 mg/dl or : 2.5 mmol/l)~Neutrophil greater than the upper limit of normal (e.g. greater than 7.0 x109 dl)~Platelets greater than the upper limit of normal (e.g. greater than 400 000)~Lactate dehydrogenase greater than 1.5 times the upper limit of normal~Fuhrmann grade of tumour~Tumour subtype e.g. clear cell vs. non-clear cell~Safety and tolerability reporting for second line axitinib~The objectives listed below will also be assessed as exploratory analyses for various patient subgroups of interest, and will be conducted if sufficient numbers of patients are available:~Axitinib PFS and OS, as a second line therapy following sunitinib, pazopanib, or following other Tyrosine kinase inhibitors (e.g. sorafenib)~Axitinib PFS and OS as a third line therapy~Axitinib PFS and OS post-immunotherapy (IO), taking into consideration 2nd and 3rd therapy lines, following all IO therapy options, E.g. atezolizumab/bevacizumab, nivolumab/ipilumimab, nivolumab, interleukin-2~For the post-sunitinib axitinib cohort: What was the duration of sunitinib therapy before patients transitioned to axitinib?~For the post-pazopanib axitinib cohort: What was the duration of sunitinib therapy before patients transitioned to axitinib?~Is the duration of therapy on first line sunitinib and/or pazopanib related to duration of therapy for second line axitinib?
Research Questions:~To understand the clinical outcomes of patients treated with sunitinib in first line and axitinib in second line in a real world setting as therapies for metastatic and/or advanced renal cell carcinoma (mRCC).~Primary Objective:~What is the progression free survival (PFS) of patients treated in first line with sunitinib, and stratified by Memorial Sloan-Kettering Cancer Center / International Metastatic Renal Cell Carcinoma Database Consortium (MSKCC/IMDC) risk category (favourable, intermediate, poor)?~What is the progression free survival (PFS) of patients treated in second line with axitinib, and stratified by MSKCC/IMDC risk category (favourable, intermediate, poor)?